Detalles de la búsqueda
1.
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Br J Haematol
; 2024 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38556836
2.
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Haematologica
; 2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38328852
3.
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Am J Hematol
; 98(11): 1751-1761, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37668287
4.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Am J Hematol
; 98(6): 848-856, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880203
5.
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Cancer
; 128(3): 529-535, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633671
6.
HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation.
N Engl J Med
; 390(7): 669-671, 2024 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38354149
7.
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(6): 1084-1090, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035275
8.
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Biol Blood Marrow Transplant
; 26(12): e322-e327, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32866594
9.
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant
; 26(2): 292-299, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536825
10.
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Am J Hematol
; 95(10): 1193-1199, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32628327
11.
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.
Haematologica
; 103(10): 1662-1668, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29903756
12.
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.
Biol Blood Marrow Transplant
; 23(4): 618-624, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28087456
13.
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Br J Haematol
; 196(6): e71-e74, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931310
14.
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.
Haematologica
; 102(12): 2030-2038, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28971906
15.
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Am J Hematol
; 96(6): E196-E200, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33719090
16.
Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Mol Carcinog
; 53(9): 722-35, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23475695
17.
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Am J Hematol
; 94(10): E253-E255, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31259427
18.
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Leuk Lymphoma
; 65(3): 372-377, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38164785
19.
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.
Int J Cancer
; 132(12): 2730-7, 2013 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23165325
20.
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Haematologica
; 103(9): e404-e407, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545346